[{"address1": "480 Pleasant Street", "address2": "Suite A-210", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 926 5000", "fax": "617 926 5050", "website": "https://eyepointpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 121, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay S. Duker M.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1294494, "exercisedValue": 0, "unexercisedValue": 3270523}, {"maxAge": 1, "name": "Ms. Isabelle  Lefebvre", "title": "Chief Regulatory Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marcia  Sellos-Moura Ph.D.", "title": "Senior Vice President of Program Leadership", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramiro  Ribeiro M.D., Ph.D.", "age": 40, "title": "Chief Medical Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anna  Kluczewska", "title": "CEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd", "fiscalYear": 2023, "totalPay": 167165, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 4, "overallRisk": 5, "governanceEpochDate": 1714348800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.63, "open": 17.42, "dayLow": 16.94, "dayHigh": 18.04, "regularMarketPreviousClose": 17.63, "regularMarketOpen": 17.42, "regularMarketDayLow": 16.94, "regularMarketDayHigh": 18.04, "beta": 1.681, "forwardPE": -6.1971836, "volume": 941725, "regularMarketVolume": 941725, "averageVolume": 984447, "averageVolume10days": 1345220, "averageDailyVolume10Day": 1345220, "bid": 17.56, "ask": 17.69, "bidSize": 100, "askSize": 200, "marketCap": 916680192, "fiftyTwoWeekLow": 5.67, "fiftyTwoWeekHigh": 30.99, "priceToSalesTrailing12Months": 19.920036, "fiftyDayAverage": 22.1726, "twoHundredDayAverage": 16.25835, "currency": "USD", "enterpriseValue": 551440960, "profitMargins": -1.53842, "floatShares": 30353430, "sharesOutstanding": 52084100, "sharesShort": 6536042, "sharesShortPriorMonth": 6579352, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.1312, "heldPercentInsiders": 0.00978, "heldPercentInstitutions": 1.01348, "shortRatio": 9.02, "shortPercentOfFloat": 0.17889999, "impliedSharesOutstanding": 52084100, "bookValue": 5.43, "priceToBook": 3.2412524, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -70795000, "trailingEps": -1.82, "forwardEps": -2.84, "lastSplitFactor": "1:10", "lastSplitDate": 1607472000, "enterpriseToRevenue": 11.983, "enterpriseToEbitda": -7.513, "52WeekChange": 1.227848, "SandP52WeekChange": 0.23099434, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "EYPT", "underlyingSymbol": "EYPT", "shortName": "EyePoint Pharmaceuticals, Inc.", "longName": "EyePoint Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1106836200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "564ca7d9-104b-3085-b6a2-17354e99fc88", "messageBoardId": "finmb_4481199", "gmtOffSetMilliseconds": -14400000, "currentPrice": 17.6, "targetHighPrice": 68.0, "targetLowPrice": 22.0, "targetMeanPrice": 43.67, "targetMedianPrice": 46.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 331049984, "totalCashPerShare": 6.643, "ebitda": -73402800, "totalDebt": 5469000, "quickRatio": 5.246, "currentRatio": 5.45, "totalRevenue": 46018000, "debtToEquity": 2.054, "revenuePerShare": 1.183, "returnOnAssets": -0.17241, "returnOnEquity": -0.39039, "freeCashflow": 15769875, "operatingCashflow": 1875000, "revenueGrowth": 0.332, "grossMargins": -0.49928, "ebitdaMargins": -1.59509, "operatingMargins": -1.08025, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]